论文部分内容阅读
测定了３２例非老年健康人、３２例老年健康人、４６例非老年慢性肺心病和５８例老年慢性肺心病患者血浆血管因子Ⅷ相关抗原（ⅧＲ～Ａｇ）浓度，并将老年慢性肺心病患者随机分为常规治疗组和抗凝治疗组。结果表明，老年健康人血浆ⅧＲ：Ａｇ浓度与非老年健康人无差异（Ｐ＞０．０５）。老年慢性肺心病患者急性发作期血浆ⅧＲ：Ａｇ浓度极显著高于老年健康人（Ｐ＜０．００１），显著高于非老年慢性肺心病急性发作期（Ｐ＜０．０５）。治疗后血浆ⅧＲ：Ａｇ浓度显著下降，而抗凝治疗较常规治疗下降更显著（Ｐ＜０．００５），但仍高于老年健康人（Ｐ＜０．０５）。表明老年慢性肺心病患者存在血液高凝状态，血浆ⅧＲ：Ａｇ是反映老年慢性肺心病高凝状态有意义的指标，抗凝治疗可明显改善老年慢性肺心病急性发作期的高凝状态。
The plasma concentrations of ⅧR ~ Ag were measured in 32 non-elderly healthy subjects, 32 elderly healthy subjects, 46 non-elderly chronic pulmonary heart disease patients and 58 elderly patients with chronic pulmonary heart disease. The levels of Ⅷ R ~ Ag in elderly patients with chronic cor pulmonale Randomly divided into conventional treatment group and anticoagulant treatment group. The results showed that plasma Ⅷ R: Ag concentration in elderly healthy people was no difference with non-elderly healthy people (P> 0.05). The plasma concentration of Ⅷ R: Ag in acute episode of elderly patients with chronic pulmonary heart disease was significantly higher than that of healthy elderly (P <0.001), significantly higher than that of non-elderly chronic pulmonary heart disease (P <0.05). After treatment, the plasma concentration of Ⅷ R: Ag was significantly decreased, while the anticoagulant therapy was more significant than the conventional treatment (P <0.005), but still higher than the elderly healthy people (P <0.05). It is indicated that there is blood hypercoagulability in elderly patients with chronic cor pulmonale. Plasma Ⅷ R: Ag is a meaningful indicator of hypercoagulability in elderly patients with chronic pulmonary heart disease. Anticoagulant therapy can significantly improve hypercoagulability in elderly patients with chronic pulmonary heart disease.